Nano-X Imaging Ltd. (NASDAQ: NNOX), a company focused on transforming medical imaging through its integrated platform, announced a securities purchase agreement with a single long-term institutional investor for a registered direct offering. The offering is expected to generate approximately $8 million in gross proceeds before fees and expenses, providing the company with additional capital to support its strategic initiatives.
Under the terms of the agreement, Nano-X will sell 8 million ordinary shares, or prefunded warrants in lieu thereof, together with warrants to purchase up to an additional 8 million ordinary shares. The combined purchase price is $1.00 per share and accompanying warrant. The warrants carry an exercise price of $1.15 per share, become exercisable six months after issuance, and expire five years after the closing. The offering is anticipated to close on or about Aug. 7, 2026, subject to customary closing conditions.
The company stated that it intends to use the net proceeds for working capital and general corporate purposes. This capital infusion comes at a critical time as Nano-X continues to advance its comprehensive medical imaging and healthcare services platform, which includes the Nanox.ARC system, AI-based solutions, and cloud-based software. The funding is expected to support ongoing operations and product development efforts.
A.G.P./Alliance Global Partners is serving as the sole placement agent for the transaction. The offering is part of Nano-X's broader strategy to drive the world's transition to preventive healthcare by making medical imaging more affordable and accessible. The company's ecosystem integrates hardware, AI, cloud infrastructure, and teleradiology services to enable earlier detection and improved clinical efficiency.
This financing move underscores investor confidence in Nano-X's vision and its potential to disrupt the traditional medical imaging market. By securing additional capital, the company is better positioned to execute its roadmap and expand its reach beyond conventional hospital settings. The funds will likely be allocated to advancing its proprietary digital X-ray technology and scaling its AI-driven analytics platform.
For more information on the offering, visit the full press release at https://ibn.fm/5fNi8. Nano-X Imaging continues to focus on delivering an end-to-end solution that lowers barriers to adoption and improves patient outcomes, and this funding is a step toward achieving those goals.
